Neoadjuvant Imatinib in Locally Advanced Gastrointestinal Stromal Tumors (GIST): The EORTC STBSG Experience
Top Cited Papers
- 13 June 2013
- journal article
- research article
- Published by Springer Science and Business Media LLC in Annals of Surgical Oncology
- Vol. 20 (9), 2937-2943
- https://doi.org/10.1245/s10434-013-3013-7
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Adjuvant and neoadjuvant imatinib therapy: Current role in the management of gastrointestinal stromal tumorsInternational Journal of Cancer, 2011
- Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trialBMC Cancer, 2011
- Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trialThe Lancet, 2009
- Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Early results of RTOG 0132/ACRIN 6665Journal of Surgical Oncology, 2008
- Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KITJournal of Clinical Oncology, 2008
- Surgical Resection of Gastrointestinal Stromal Tumors After Treatment with ImatinibAnnals of Surgical Oncology, 2006
- Impact of Surgery on Advanced Gastrointestinal Stromal Tumors (GIST) in the Imatinib EraAnnals of Surgical Oncology, 2006
- KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumoursEuropean Journal Of Cancer, 2006
- Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: a centre-based study of 17 patientsBritish Journal of Cancer, 2003
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsNew England Journal of Medicine, 2002